Worksite Tobacco Prevention: A Randomized, Controlled Trial of Adoption, Dissemination Strategies, and Aggregated Health-Related Outcomes across Companies

Table 2

Longitudinal changes with regard to worksite TP and health-related outcomes aggregated at company level (Wilcoxon tests).

			Decrease	No change	Increase
Worksite TP^1
Restrictiveness of smoking policy	2	3	9.4%	68.5%	22.1%	809	−5.941	<.001	−0.21
Number of individual support measures	0	0	9.1%	78.8%	12.1%	827	−1.609	.054	−0.06
SOC^2 smoke-free policy	4	5	12.6%	54.8%	32.6%	786	−7.666	<.001	−0.27
SOC^2 cessation courses	1	1	16.1%	65.6%	18.3%	771	−2.376	.009	−0.09
Health-related outcomes aggregated at company level
% smokers in the workforce^3	2	2	17.7%	56.0%	26.3%	723	−3.254	<.001	−0.12
SHS^4-related problems^5	1	1	31.4%	49.0%	19.6%	816	−6.195	<.001	−0.22
Absenteeism due to illness^5	2	2	27.0%	46.3%	26.8%	800	−0.790	.215	−0.03

Note.  Median.
Effect size.
¹For scale coding, see Table 1.
²Stage of change.
³1 = 0–20%, 5 = 80–100%.
⁴Environmental tobacco smoke.
⁵Answers were given on a five-point scale from 1 (“does not apply”) to 5 (“applies”).